A Phase 2 interventional study of Tezepelumab Dose 1 and Tezepelumab Dose 2 in Chronic Spontaneous Urticaria, sponsored by Amgen. Completed at 81 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-09.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.
Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 23rd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2021, is one of 23 in phase 2, and was the 31st registered.
197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.
Browse Chronic Urticaria studies →9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 25 · Phase 3 22 · Phase 4 4
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 132 across the 58 interventional studies, 428 across the 6 observational. Of the 44 that completed or were terminated, 30 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 64 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 1 study filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
6 of the studies in Chronic Urticaria with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT07540910Enanta Pharmaceuticals, IncA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults | 2026-11 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT06931405Blueprint Medicines CorporationStudy of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | 2026-12-31 |
| NCT06927999ARS Pharmaceuticals, Inc.An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Chronic Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Disease related, including but not limited to:
Other medical conditions
Prior/concomitant therapy, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants naive to anti-IgE therapies will receive omalizumab.
Biological: Omalizumab
Participants naive to anti-IgE therapies will receive a placebo.
Biological: Placebo
Participants naive to anti-IgE therapies will receive tezepelumab.
Biological: Tezepelumab Dose 1
Participants naive to anti-IgE therapies will receive tezepelumab.
Biological: Tezepelumab Dose 2
Participants previously treated with anti-IgE therapies will receive a placebo.
Biological: Placebo
Participants previously treated with anti-IgE therapies will receive tezepelumab.
Biological: Tezepelumab Dose 1
Participants previously treated with anti-IgE therapies will receive tezepelumab.
Biological: Tezepelumab Dose 2
Subcutaneous injection.
Also known as: AMG 157
Subcutaneous injection.
Also known as: AMG 157
Subcutaneous injection.
Also known as: Xolair
Subcutaneous injection.
Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16
The UAS is a CSU-specific patient-reported outcome measure with 2 components: Hives Severity Score (HSS) for number of wheals and an Itch Severity Score (ISS) for itch intensity, and are each scored from 0 (no wheals, no itch) to 3 (\>50 wheals, severe itch) for the previous 24 hours. The HSS and ISS are combined to give a daily UAS ranging from 0 to 6. The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). The least squares mean (LSM) estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UAS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
Time frame: Baseline and Week 16
Change From Baseline in ISS Over 7 Days (ISS7) at Week 16
The ISS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed itch intensity, with daily scores ranging from 0 (no itch) to 3 (severe itch) for the previous 24 hours. The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline ISS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
Time frame: Baseline and Week 16
Change From Baseline in HSS Over 7 Days (HSS7) at Week 16
The HSS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed the number of wheals, with daily scores ranging from 0 (no wheals) to 3 (\>50 wheals) for the previous 24 hours. The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline HSS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
Time frame: Baseline and Week 16
Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal residual disease in UAS7 was defined as a score ≤ 6 and indicates well-controlled urticaria and a good response to treatment.
Time frame: Week 16
Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference)
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal important difference in UAS7 was defined as a change from baseline of ≤ -10.
Time frame: Baseline and Week 16
Number of Participants With a UAS7 = 0 at Week 16 (Complete Response)
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). A complete response was defined as UAS7 = 0 at Week 16.
Time frame: Week 16
Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution)
The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). An ISS7 = 0 indicates a complete resolution of itch.
Time frame: Week 16
Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference)
The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). Minimal important difference in ISS7 was defined as a change from baseline of ≤ -5.
Time frame: Baseline and Week 16
Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution)
The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). An HSS7 = 0 indicates a complete resolution of hives.
Time frame: Week 16
Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference)
The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). Minimal important difference in HSS7 was defined as a change from baseline of ≤ -5.5.
Time frame: Baseline and Week 16
Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16
The SIS is part of the Urticaria Patient Daily Diary and was assessed by the participant using the electronic diary once daily in the morning. Participants scored sleep interference on a scale of 0 (no interference) to 3 (substantial, woke up often, severe interference with sleep). The SIS7 was a sum of the daily scores over 7 days ranging from 0 to 21. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SIS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep interference.
Time frame: Baseline and Week 16
Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16
The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of the 3 daily sleep quality items over 7 days, ranged from 0 (good quality sleep) to 63 (poor quality sleep). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of SQS, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.
Time frame: Baseline and Week 16
Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16
The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of average daily Q1 - Q3 score was generated by averaging 3 daily sleep quality items and then summing the daily average over 7 days with a score ranging from 0 (good quality sleep) to 21 (poor quality sleep) (sum of the average daily Q1 - Q3). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of average daily Q1 - Q3, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.
Time frame: Baseline and Week 16
Change From Baseline in Urticaria Control Test (UCT) Score at Week 16
The UCT assesses disease control in participants with CSU through a retrospective validated scoring system, evaluating the physical symptoms of chronic urticaria (itch, hives and/or angioedema) and the effectiveness of treatment over 4 weeks. It consists of 4 questions with 5 answer options, scored from 0 to 4, and the UCT score is the sum of all 4 questions, with total score ranging from 0 (no control) to 16 (complete control). A score of ≥ 12 indicates well-controlled urticaria and a score of ≤ 11 points indicates poor disease control. A positive change from baseline indicates an improvement in disease control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UCT score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16
The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Negative changes from baseline indicate an improvement in angioedema activity. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AAS7, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free)
The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Angioedema occurrence free was defined as AAS7 = 0.
Time frame: Baseline to Week 16
Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16
The CU-Q2oL is a 23-item, self-reported urticaria-specific measure to evaluate 6 dimensions of quality of life (QoL): pruritus, impact on life activities, sleep problems, limitations, looks, and swelling. The total score is transformed to a linear scale of 0 to 100 with a higher CU-Q2oL score indicating a higher QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline CU-Q2oL score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16
The DLQI is a 10-item, participant-completed, health-related QoL assessment with content specific to those with dermatology conditions. The DLQI evaluates participant perceptions including dermatology-related symptoms and feelings, impacts on daily activities, leisure, work or school, personal relationships, and side effects of treatment. The recall period was 1 week. The DLQI total score ranges from 0 to 30 with a higher score indicating a greater QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline DLQI score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16
The AE-QoL is a validated angioedema QoL questionnaire for participants with angioedema. It consists of 17 questions evaluating 4 domains including functioning, fatigue/mood, fear/shame, and food with a recall period of 4 weeks. The total score is transformed to a linear scale ranging from 0 to 100, with a higher score indicating a worse impairment in QoL. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AE-QoL score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16
The AECT is a patient-reported outcome measure to evaluate disease control in the domains of signs and symptoms, QoL, anxiety/fear, and effectiveness of therapy. The total AECT score ranges from 0 to 16, with higher scores indicating well-controlled disease. A positive change from baseline indicates an improvement in angioedema control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AECT score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Number of Participants With an AECT Score = 16 at Week 16 (Complete Control)
The total AECT score ranges from 0 to 16, with higher scores indicating better controlled disease. Complete control was defined as AECT score = 16.
Time frame: Baseline and Week 16
Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16
The WPAI-CU is a questionnaire that assesses the impact of an intervention on work productivity, evaluating 4 areas including absenteeism, presenteeism, work productivity loss, and activity impairment over the past 7 days. Each of the areas is scored separately as a percentage, ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity. A negative change from baseline indicates an improvement. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline WPAI-CU score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16
Participants recorded any need of sgAH rescue medication in their daily electronic diary.
Time frame: Baseline to Week 16
Serum Concentration of Tezepelumab
The lower limit of quantification was 10 ng/mL, and values below this limit were set to zero.
Time frame: Week 1 pre-dose, Weeks 2, 4, 8, 12, 16, 24, and 32
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with study treatment. TEAEs were AEs that started on or after the first dose of investigational product up to the end of study (Week 32). A serious AE (SAE) was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: immediately life-threatening, required hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event.
Time frame: Day 1 Week 1 to Week 32, up to 32 weeks
Participants were enrolled at 56 study centers in Japan, Republic of Korea, France, Germany, Greece, Italy, Poland, Spain, Canada, and the United States, and participated from 15 April 2021 to 13 April 2023.
| Milestone | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Started | 48 | 31 | 52 | 52 |
| Completed | 43 | 29 | 45 | 48 |
| Not completed | 5 | 2 | 7 | 4 |
| Withdrew: Decision by sponsor | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 2 |
| Withdrew: Protocol specified criteria | 0 | 0 | 2 | 1 |
The UAS is a CSU-specific patient-reported outcome measure with 2 components: Hives Severity Score (HSS) for number of wheals and an Itch Severity Score (ISS) for itch intensity, and are each scored from 0 (no wheals, no itch) to 3 (\>50 wheals, severe itch) for the previous 24 hours. The HSS and ISS are combined to give a daily UAS ranging from 0 to 6. The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). The least squares mean (LSM) estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UAS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 | -13.6 ± 1.6 | -18.4 ± 2.0 | -13.5 ± 1.6 | -14.7 ± 1.5 |
The ISS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed itch intensity, with daily scores ranging from 0 (no itch) to 3 (severe itch) for the previous 24 hours. The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline ISS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in ISS Over 7 Days (ISS7) at Week 16 | -7.7 ± 0.8 | -9.6 ± 1.0 | -7.3 ± 0.8 | -8.0 ± 0.8 |
The HSS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed the number of wheals, with daily scores ranging from 0 (no wheals) to 3 (\>50 wheals) for the previous 24 hours. The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline HSS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in HSS Over 7 Days (HSS7) at Week 16 | -5.8 ± 0.8 | -8.8 ± 1.1 | -6.3 ± 0.8 | -6.7 ± 0.8 |
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal residual disease in UAS7 was defined as a score ≤ 6 and indicates well-controlled urticaria and a good response to treatment.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16 | 8 | 14 | 10 | 13 |
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal important difference in UAS7 was defined as a change from baseline of ≤ -10.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference) | 28 | 20 | 27 | 32 |
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). A complete response was defined as UAS7 = 0 at Week 16.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Participants With a UAS7 = 0 at Week 16 (Complete Response) | 4 | 11 | 7 | 5 |
The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). An ISS7 = 0 indicates a complete resolution of itch.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution) | 4 | 12 | 7 | 9 |
The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). Minimal important difference in ISS7 was defined as a change from baseline of ≤ -5.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference) | 29 | 20 | 28 | 34 |
The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). An HSS7 = 0 indicates a complete resolution of hives.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution) | 6 | 11 | 8 | 6 |
The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). Minimal important difference in HSS7 was defined as a change from baseline of ≤ -5.5.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference) | 23 | 19 | 24 | 31 |
The SIS is part of the Urticaria Patient Daily Diary and was assessed by the participant using the electronic diary once daily in the morning. Participants scored sleep interference on a scale of 0 (no interference) to 3 (substantial, woke up often, severe interference with sleep). The SIS7 was a sum of the daily scores over 7 days ranging from 0 to 21. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SIS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep interference.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16 | -8.4 ± 0.7 | -6.5 ± 0.9 | -7.4 ± 0.7 | -7.8 ± 0.7 |
The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of the 3 daily sleep quality items over 7 days, ranged from 0 (good quality sleep) to 63 (poor quality sleep). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of SQS, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16 | -19.5 ± 1.8 | -16.7 ± 2.3 | -18.3 ± 1.7 | -17.1 ± 1.6 |
The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of average daily Q1 - Q3 score was generated by averaging 3 daily sleep quality items and then summing the daily average over 7 days with a score ranging from 0 (good quality sleep) to 21 (poor quality sleep) (sum of the average daily Q1 - Q3). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of average daily Q1 - Q3, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16 | -6.5 ± 0.6 | -5.6 ± 0.8 | -6.1 ± 0.6 | -5.7 ± 0.5 |
The UCT assesses disease control in participants with CSU through a retrospective validated scoring system, evaluating the physical symptoms of chronic urticaria (itch, hives and/or angioedema) and the effectiveness of treatment over 4 weeks. It consists of 4 questions with 5 answer options, scored from 0 to 4, and the UCT score is the sum of all 4 questions, with total score ranging from 0 (no control) to 16 (complete control). A score of ≥ 12 indicates well-controlled urticaria and a score of ≤ 11 points indicates poor disease control. A positive change from baseline indicates an improvement in disease control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UCT score, treatment, study week and the interaction between treatment and study week.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in Urticaria Control Test (UCT) Score at Week 16 | 4.1 ± 0.6 | 6.3 ± 0.8 | 4.9 ± 0.6 | 5.9 ± 0.6 |
The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Negative changes from baseline indicate an improvement in angioedema activity. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AAS7, treatment, study week and the interaction between treatment and study week.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16 | -19.0 ± 2.7 | -18.7 ± 3.5 | -20.8 ± 2.7 | -15.6 ± 2.5 |
The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Angioedema occurrence free was defined as AAS7 = 0.
| weeks | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free) | 10.8 ± 5.2 | 11.3 ± 4.9 | 9.9 ± 5.8 | 11.5 ± 5.4 |
The CU-Q2oL is a 23-item, self-reported urticaria-specific measure to evaluate 6 dimensions of quality of life (QoL): pruritus, impact on life activities, sleep problems, limitations, looks, and swelling. The total score is transformed to a linear scale of 0 to 100 with a higher CU-Q2oL score indicating a higher QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline CU-Q2oL score, treatment, study week and the interaction between treatment and study week.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16 | -19.6 ± 2.1 | -19.8 ± 2.8 | -19.3 ± 2.2 | -18.7 ± 2.1 |
The DLQI is a 10-item, participant-completed, health-related QoL assessment with content specific to those with dermatology conditions. The DLQI evaluates participant perceptions including dermatology-related symptoms and feelings, impacts on daily activities, leisure, work or school, personal relationships, and side effects of treatment. The recall period was 1 week. The DLQI total score ranges from 0 to 30 with a higher score indicating a greater QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline DLQI score, treatment, study week and the interaction between treatment and study week.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16 | -7.4 ± 0.9 | -7.3 ± 1.2 | -7.0 ± 0.9 | -7.0 ± 0.9 |
The AE-QoL is a validated angioedema QoL questionnaire for participants with angioedema. It consists of 17 questions evaluating 4 domains including functioning, fatigue/mood, fear/shame, and food with a recall period of 4 weeks. The total score is transformed to a linear scale ranging from 0 to 100, with a higher score indicating a worse impairment in QoL. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AE-QoL score, treatment, study week and the interaction between treatment and study week.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16 | -29.2 ± 6.0 | -24.1 ± 10.9 | -24.6 ± 6.4 | -13.1 ± 7.4 |
The AECT is a patient-reported outcome measure to evaluate disease control in the domains of signs and symptoms, QoL, anxiety/fear, and effectiveness of therapy. The total AECT score ranges from 0 to 16, with higher scores indicating well-controlled disease. A positive change from baseline indicates an improvement in angioedema control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AECT score, treatment, study week and the interaction between treatment and study week.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16 | 4.2 ± 1.2 | 3.9 ± 2.2 | 4.6 ± 1.3 | 2.3 ± 1.5 |
The total AECT score ranges from 0 to 16, with higher scores indicating better controlled disease. Complete control was defined as AECT score = 16.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Participants With an AECT Score = 16 at Week 16 (Complete Control) | 3 | 2 | 0 | 1 |
The WPAI-CU is a questionnaire that assesses the impact of an intervention on work productivity, evaluating 4 areas including absenteeism, presenteeism, work productivity loss, and activity impairment over the past 7 days. Each of the areas is scored separately as a percentage, ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity. A negative change from baseline indicates an improvement. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline WPAI-CU score, treatment, study week and the interaction between treatment and study week.
| score on a scale | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Absenteeism | -4.7 ± 2.5 | 0.3 ± 3.0 | -7.5 ± 2.5 | -2.3 ± 2.7 |
| Presenteeism | -19.9 ± 5.2 | -18.3 ± 6.6 | -20.3 ± 5.3 | -17.8 ± 5.7 |
| Work productivity loss | -20.0 ± 5.4 | -13.3 ± 6.7 | -23.5 ± 5.5 | -17.5 ± 5.9 |
| Activity impairment | -28.5 ± 4.2 | -30.3 ± 5.6 | -27.2 ± 4.3 | -24.1 ± 4.1 |
Participants recorded any need of sgAH rescue medication in their daily electronic diary.
| days | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16 | 49.5 ± 39.0 | 31.6 ± 42.7 | 46.1 ± 39.3 | 32.7 ± 33.4 |
The lower limit of quantification was 10 ng/mL, and values below this limit were set to zero.
| µg/mL | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|
| Week 1 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 2 | 20.1 ± 6.93 | 41.3 ± 12.4 |
| Week 4 | 14.2 ± 5.78 | 71.3 ± 20.8 |
| Week 8 | 21.2 ± 8.54 | 101 ± 30.5 |
| Week 12 | 24.8 ± 9.67 | 123 ± 44.1 |
| Week 16 | 27.1 ± 10.7 | 136 ± 43.4 |
| Week 24 | 6.95 ± 5.65 | 37.3 ± 21.1 |
| Week 32 | 1.73 ± 1.73 | 11.0 ± 10.8 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with study treatment. TEAEs were AEs that started on or after the first dose of investigational product up to the end of study (Week 32). A serious AE (SAE) was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: immediately life-threatening, required hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event.
| Participants | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| TEAEs | 23 | 24 | 29 | 28 |
| SAEs | 0 | 1 | 1 | 0 |
Collected over All-cause mortality was collected from enrolment to the end of study visit, up to 38 weeks. SAEs and other AEs were collected from Day 1 up to Week 32, up to 32 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/48 (0%) | 0/48 (0%) | 14/48 (29.2%) |
| Omalizumab 300 mg SC Q4W | 0/31 (0%) | 1/31 (3.2%) | 7/31 (22.6%) |
| Tezepelumab 210 mg SC Q4W | 0/52 (0%) | 1/52 (1.9%) | 19/52 (36.5%) |
| Tezepelumab 420 mg SC Q2W | 0/52 (0%) | 0/52 (0%) | 20/52 (38.5%) |
| Event | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| Intentional self-injuryPsychiatric disorders | 0/48 | 1/31 | 0/52 | 0/52 |
| Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/48 | 0/31 | 1/52 | 0/52 |
| Event | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W |
|---|---|---|---|---|
| COVID-19Infections and infestations | 3/48 | 2/31 | 8/52 | 5/52 |
| HeadacheNervous system disorders | 2/48 | 1/31 | 5/52 | 6/52 |
| PyrexiaGeneral disorders | 1/48 | 3/31 | 3/52 | 2/52 |
| UrticariaSkin and subcutaneous tissue disorders | 4/48 | 0/31 | 4/52 | 3/52 |
| Injection site painGeneral disorders | 1/48 | 0/31 | 4/52 | 1/52 |
| EczemaSkin and subcutaneous tissue disorders | 3/48 | 1/31 | 2/52 | 0/52 |
| NasopharyngitisInfections and infestations | 2/48 | 1/31 | 1/52 | 3/52 |
| Back painMusculoskeletal and connective tissue disorders | 0/48 | 0/31 | 1/52 | 3/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/48 | 0/31 | 2/52 | 3/52 |
| Age, Continuous(years) | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W | Total |
|---|---|---|---|---|---|
| Mean | 42.8 ± 15.2 | 39.8 ± 13.1 | 45.0 ± 14.7 | 42.9 ± 14.5 | 42.9 ± 14.5 |
| Sex: Female, Male(Participants) | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W | Total |
|---|---|---|---|---|---|
| Female | 37 | 23 | 35 | 39 | 134 |
| Male | 11 | 8 | 17 | 13 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 3 | 6 | 14 |
| Not Hispanic or Latino | 45 | 29 | 49 | 46 | 169 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W | Total |
|---|---|---|---|---|---|
| Asian | 18 | 12 | 16 | 14 | 60 |
| Black or African American | 1 | 2 | 2 | 2 | 7 |
| Multiple | 0 | 0 | 0 | 1 | 1 |
| White | 29 | 17 | 34 | 34 | 114 |
| Other | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Apr 2021 to primary completion in Dec 2022, 20 months.
Results were first posted in May 2024, 1 year 4 months after primary completion. A results delay was requested in Aug 2023.
Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab